Welcome to our dedicated page for Aurora Cannabis news (Ticker: ACB), a resource for investors and traders seeking the latest updates and insights on Aurora Cannabis stock.
Aurora Cannabis Inc. reports developments in its global medical cannabis business, including product launches, brand expansion and regulated-market activity across Canada, Europe, Australia and New Zealand. The company serves medical and consumer cannabis markets through brands such as Aurora, MedReleaf, Pedanios, IndiMed, San Raf, Tasty's and Whistler, with GMP-certified manufacturing facilities in Canada and Germany.
Recurring announcements cover new formats such as dried flower, pre-rolls, pastilles and resin cartridges; operating and financial results; international market engagement; capital actions; and governance updates. Aurora's news also reflects its medical-first strategy and use of a global manufacturing network to supply regulated cannabis markets.
Aurora Cannabis (NASDAQ: ACB) filed a prospectus supplement on February 4, 2026 establishing an at-the-market offering (ATM) program to issue up to U.S.$100 million of common shares from treasury. Proceeds are intended for strategic, accretive uses, including increased cultivation capacity and M&A.
Sales will occur via at-the-market distributions on NASDAQ or other U.S. marketplaces and may include privately negotiated transactions; no sales will be made on Canadian stock exchanges. The ATM is governed by a sales agreement with TD Securities (USA) LLC and the prospectus supplement and registration statement are filed in Canada (except Quebec) and with the SEC.
Aurora Cannabis (NASDAQ: ACB) reported Q3 FY2026 results for the quarter ended December 31, 2025. Total net revenue rose 7% YoY to $94.2M, led by a record global medical cannabis revenue of $76.2M (+12%). Adjusted EBITDA was $18.5M, adjusted net income $7.2M, and free cash flow $15.5M. The company holds $154.4M of cash and short-term investments and says its cannabis business is debt-free aside from a $62M non-recourse Bevo Farms liability. Management reaffirmed FY2026 guidance for medical revenue of $269M–$281M and FY adjusted EBITDA of $52M–$57M.
Aurora (NASDAQ: ACB) launched four new, localized European websites on Feb 3, 2026 to support key medical markets and a central hub at auroramedicine.com.
The sites target Germany, the UK and Poland in native languages, spotlight Canadian and local manufacturing, emphasize science-backed quality and provide resources for healthcare professionals, partners and prospective employees to strengthen regional engagement.
Aurora Cannabis (NASDAQ: ACB) will host a conference call to discuss third quarter 2026 results on Wednesday, February 4, 2026 at 8:00 a.m. Eastern Time (6:00 a.m. Mountain). The company will release Q3 2026 financial results before market open the same day.
Miguel Martin, Executive Chairman and CEO, and Simona King, CFO, will host the call and Q&A. A live webcast link is posted under the company’s Investor Info > Events page at https://www.auroramj.com/investors/.
Aurora Cannabis (NASDAQ: ACB) announced it has been granted Community Plant Variety Rights by the EU Community Plant Variety Office for two proprietary Cannabis sativa L varieties: SOT20R07-007 (Farm Gas™) and ACB21T044 (Sourdough™) on Jan 20, 2026.
The varieties were bred in Canada and are described as high-potency, aromatic, consistent cultivars available to medical patients in Germany, Poland, UK, Canada, and Australia. The EU rights provide exclusive commercial control across the 27 EU member states for the protection period and strengthen Aurora's global genetics portfolio.
Aurora (NASDAQ: ACB) reported significant progress in its powdery mildew (PM) resistance research, nearly one year after discovering a novel genetic resistance source called PM2. The company said it has performed multiple crosses to introgress PM2 into elite breeding lines and run controlled infection and production trials at its Aurora Ridge facility to validate durability and preserve quality traits.
The proprietary marker technology was developed at Aurora Coast with prior UBC collaboration and Genome British Columbia funding; related IP is patent pending in several jurisdictions. Commercialization of PM-resistant cultivars is planned later this year if production trials succeed.
Aurora (NASDAQ: ACB) launched Daily Special, a medical cannabis brand for the German market, available at German pharmacies and via telemedicine from December 19, 2025. The rollout targets affordability and consistent, pharmaceutical‑grade supply backed by global GMP production standards. The initial SKU is a sativa‑dominant Gelonade × Biscotti cultivar with a reported 21–23% THC and <1% CBD, described as citrus, sweet‑earthy and diesel in aroma.
Aurora presents the launch as an expansion of its medical portfolio in Germany, emphasized as one of the company's fastest growing markets, and positions Daily Special to increase patient choice and affordability while leveraging Aurora's global genetic library and production capacity.
Aurora Cannabis (NASDAQ: ACB) launched Black Jelly, a proprietary high-potency medical cannabis cultivar, in Poland on December 11, 2025. Black Jelly offers a cannabinoid profile of THC 27% / CBD <1% and is described as a high-THC sativa derived from Alien Cake 3030 × T037 with sweet black liquorice and fruity terpenes.
The product is grown and manufactured in Aurora's Canadian GACP and EU-GMP certified facilities and joins Farm Gas and Sourdough under the Cannabis flos Aurora portfolio. Aurora said Black Jelly is available to Polish prescribers immediately and emphasized its genetics program, hang-drying and curing techniques, and decade-plus international medical market experience.
Aurora Cannabis (NASDAQ: ACB) named Kerry Miller as Managing Director for Australia and New Zealand, effective January 15, 2026. Miller is a 35-year consumer packaged goods executive with a 25-year tenure at Reckitt Benckiser and nearly 10 years at Unilever.
The company said Miller will drive growth in the Australia and New Zealand markets, leveraging experience leading global teams and large transformation programs across Australia, UK, USA, Europe, Africa, Middle East and Asia. Miller stated he aims to accelerate innovation, strengthen partnerships, and expand access to medical cannabis for patients and stakeholders in the region.
Aurora (NASDAQ: ACB) announced on December 2, 2025 that its subsidiary MedReleaf Australia has signed a distribution partnership with Leafio, the wholesale arm of Montu Australia. The agreement appoints Leafio as a wholesaler for Aurora's medical cannabis brands MedReleaf, CraftPlant, Aurora, Whistler Cannabis Co., and IndiMed and will distribute TGA‑GMP certified products through Leafio's nationwide supply chain.
The arrangement will support clinician education and clinical support for prescribers, and enable distribution to a network that services over 4,000 pharmacies across Australia, aiming to expand patient access and research collaboration.